APA (7th ed.) Citation

Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., . . . Hooper, G. (2026). Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. Neurology & Therapy, 15(2), 545. https://doi.org/10.1007/s40120-025-00879-8

Chicago Style (17th ed.) Citation

Mendell, Jerry R., et al. "Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial." Neurology & Therapy 15, no. 2 (2026): 545. https://doi.org/10.1007/s40120-025-00879-8.

MLA (9th ed.) Citation

Mendell, Jerry R., et al. "Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial." Neurology & Therapy, vol. 15, no. 2, 2026, p. 545, https://doi.org/10.1007/s40120-025-00879-8.